Previous 10 | Next 10 |
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS ® (omaveloxolone), the first and only FDA approved treatment for Friedreich’s ataxia in the U.S. CAMBRIDGE, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (N...
2023-09-25 06:55:38 ET More on Biogen, Eisai, etc. Eisai: Lumpy Rollout Of Leqembi, Economic Value Hard To Ascertain (Rating Downgrade) Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And...
TOKYO and CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today th...
2023-09-23 16:00:00 ET More on GE Healthcare, Siemens, Biogen GE Healthcare: Revenue Growth, Margin Expansion And Attractive Valuation Siemens Healthineers: The Decline Makes The Upside Better Why Did GE HealthCare Excel Beyond The COVID-19 Crisis? Biogen: Le...
2023-09-21 10:36:52 ET More on Biogen, Reata, etc. Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play Biogen Q2 2023 Analysis: Reata Acquisition, Financials, And Alzheimer's Prospects Biogen's Bold $7.3B Acquisition Of Reata: Analyzing The Impact...
2023-09-19 12:44:41 ET More on Scholar Rock Seeking Alpha’s Quant Rating on Scholar Rock Historical earnings data for Scholar Rock Financial information for Scholar Rock Scholar Rock: The Market Isn't Enthusiastic Despite Decent Clinical Data F...
2023-09-15 17:37:08 ET More on Novartis Seeking Alpha’s Quant Rating on Novartis Historical earnings data for Novartis Dividend scorecard for Novartis Financial information for Novartis Novartis: Q2 Beats Expectations, But Still Pricey ...
2023-09-15 15:00:00 ET More on the markets Key Region Of Support Sides With SPY Bullish Case Market Crosswinds And Nasdaq Looking Better Than Dow The Fed's rate-hike cycle has 'most assuredly ended' -- Lawrence Fuller Fund managers finally embrace U.S. stocks...
2023-09-13 16:02:03 ET Summary On July 25, 2023, GE HealthCare Technologies, one of the leading companies in developing and commercializing medical devices and pharmaceutical diagnostics, published financial results for the second quarter of 2023. GE HealthCare's revenue amounted ...
2023-09-12 15:49:54 ET More on Biogen Seeking Alpha’s Quant Rating on Biogen Historical earnings data for Biogen Financial information for Biogen Biogen Inc. ( BIIB ) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript) Stoc...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, Mass., July 02, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases ...
TOKYO and CAMBRIDGE, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today tha...
NEW YORK, NY / ACCESSWIRE / June 12, 2024 / Leading law firm Bleichmar Fonti & Auld LLP announces the upcoming July 22, 2024, deadline in the Biogen Inc. (Nasdaq:BIIB) Securities Class Action Lawsuit. If you invested in Biogen, you are encouraged to obtain additional information by visiting ...